Treatment of Irritability in Personality Disorders
Psychotherapy, specifically dialectical behavior therapy (DBT), transference-focused psychotherapy, or schema therapy, should be the primary treatment for irritability in personality disorders, with low-dose atypical antipsychotics (olanzapine or quetiapine) considered only as adjunctive therapy when psychotherapy alone is insufficient.
Psychotherapy as First-Line Treatment
Structured psychotherapy is the cornerstone of treatment for personality disorders and associated irritability. 1, 2
DBT, transference-focused psychotherapy, and schema therapy all demonstrate efficacy for reducing irritability and aggression in borderline personality disorder (BPD). 3, 2
Transference-focused psychotherapy showed particular effectiveness for irritability reduction, with significant improvements in irritability, verbal assault, and direct assault over one year of treatment. 3
DBT combined with medication resulted in large and consistent reductions in irritability and aggression across treatment groups. 4
Group therapy formats should be approached cautiously as they result in higher dropout rates than individual therapy. 2
Pharmacological Augmentation Strategy
When to Consider Medication
Pharmacotherapy should only be considered as an adjunct to BPD-specific psychotherapy, never as monotherapy. 5
Medications are most useful for treating circumscribed symptom domains like impulsivity and aggression, inducing only partial improvement. 6
Atypical Antipsychotics
Low-dose olanzapine (typical dosage not specified in studies, but described as "low-dose") may promote more rapid reduction of irritability and aggression when combined with DBT. 4
Quetiapine at 600-800 mg daily demonstrated effectiveness in decreasing impulsivity, hostility, aggressiveness, and irritability in antisocial personality disorder. 7
The favorable adverse-event profile of quetiapine improves medication compliance. 7
Quetiapine can be successfully combined with mood stabilizers, particularly gabapentin, when prominent affective instability is present. 7
Critical Caveats
Polypharmacy and unsafe drugs with overdose risk must be avoided in personality disorder populations. 5
Pharmacological studies rarely report harms adequately, making side-effect-based recommendations challenging. 8
No medications are FDA-approved specifically for personality disorders; all use is off-label. 5
Cognitive Considerations
Higher cognitive functioning is associated with better outcomes for irritability treatment. 8
Irritability is conceptualized as mood dysregulation with a clear cognitive component, not merely observable behavior. 8
For irritability specifically, interventions with a cognitive rather than purely behavioral approach may be most appropriate. 8
Individuals with lower developmental ability may score higher on irritability measures due to fewer cognitive resources for mood regulation, rather than actual behavioral differences. 8
Treatment Duration and Intensity
Longer, more intensive therapy does not appear more effective than shorter, less intensive approaches for BPD. 2
One year of structured outpatient treatment shows significant improvements across multiple domains including irritability. 3
Treatment effects appear to maintain at follow-up, suggesting durability of improvements. 8
Evidence Limitations
Most available evidence concentrates on borderline and schizotypal personality disorders, with limited data for other personality disorder types. 6
There is no consensus on whether any single psychological intervention is preferable over others. 1
Clinical guidelines show notable lack of agreement on pharmacological recommendations for personality disorders. 5